Log in
AI

Alphabet Inc

Alphabet Inc · Investor
1Y performance ⓘ
+70%
AUM (13F)
$4.0B
# of Holdings
26
3Y performance ⓘ
+155%
vs S&P 500 ⓘ
+76%
Updated
Mar 31

Alphabet Inc's Alphabet Inc holds 26 U.S.-equity positions worth $4.0B (SEC 13F, Q1 2026). Top positions: CME Group Inc. 25.6%, Planet Labs PBC 24.5%, AST SpaceMobile, Inc. Class A Common Stock 18.5%. 13F-replication return is +155% over 3 years (+76 pts vs the S&P 500) — a replicated, non-audited figure.

Holdings

Stock% of portfolio SharesValue Latest activityAvg buy price Current priceDate
CME CME Group Inc. 25.6% 3.5M $1.0B NEW (+3.5M) $295.35 $266.09 (−10%) 2026-03-31
PL Planet Labs PBC 24.5% 35.2M $985M ▲ 10% (+3.3M) $6.18 $16.27 (+163%) 2026-03-31
ASTS AST SpaceMobile, Inc. Class A Common Stock 18.5% 8.9M $741M — $22.74 $58.00 (+155%) 2026-03-31
RVMD Revolution Medicines, Inc. Common Stock 8.0% 3.3M $320M ▼ 1.6% (−53K) $28.69 $207.73 (+624%) 2026-03-31
ARM Arm Holdings Plc 7.4% 2.0M $297M — $53.52 $291.95 (+445%) 2026-03-31
FRSH Freshworks Inc. Class A Common Stock 3.2% 16.2M $130M — $15.89 $13.11 (−18%) 2026-03-31
PATH UiPath, Inc. 1.9% 7.0M $78M — $17.56 $13.09 (−25%) 2026-03-31
TEM Tempus AI, Inc. Class A Common Stock 1.8% 1.6M $70M — $35.00 $81.35 (+132%) 2026-03-31
PAYP Paypay Corp 1.7% 3.1M $67M NEW (+3.1M) $21.34 $15.73 (−26%) 2026-03-31
GTLB GitLab Inc. Class A Common Stock 1.5% 2.7M $59M — $53.03 $48.04 (−9%) 2026-03-31
PRME Prime Medicine, Inc. Common Stock 1.4% 16.6M $58M — $10.66 $3.06 (−71%) 2026-03-31
LIFE Ethos Technologies Inc. Class A Common Stock 1.1% 3.8M $42M NEW (+3.8M) $11.17 $33.54 (+200%) 2026-03-31
MAZE Maze Therapeutics, Inc. Common Stock 1.0% 1.4M $41M — $11.01 $27.22 (+147%) 2026-03-31
BBOT BridgeBio Oncology Therapeutics, Inc. Common Stock 0.6% 2.8M $25M — $11.58 $4.07 (−65%) 2026-03-31
RLAY Relay Therapeutics, Inc. Common Stock 0.4% 1.6M $16M — $12.56 $18.50 (+47%) 2026-03-31
GLUE Monte Rosa Therapeutics, Inc. Common Stock 0.3% 684K $11M ▼ 8.1% (−61K) $7.79 $11.46 (+47%) 2026-03-31
VERA Vera Therapeutics, Inc. Class A Common Stock 0.2% 241K $10M — $7.76 $32.23 (+315%) 2026-03-31
SANA Sana Biotechnology, Inc. Common Stock 0.2% 2.8M $8M — $3.27 $2.92 (−11%) 2026-03-31
BEAM Beam Therapeutics Inc. Common Stock 0.2% 322K $8M — $30.62 $24.45 (−20%) 2026-03-31
LYEL Lyell Immunopharma, Inc. Common Stock 0.1% 293K $6M — $8.84 $9.97 (+13%) 2026-03-31
OSCR Oscar Health, Inc. 0.1% 482K $6M — $8.03 $30.79 (+283%) 2026-03-31
FIG Figma, Inc. 0.1% 216K $5M — $51.87 $21.66 (−58%) 2026-03-31
SPRO Spero Therapeutics, Inc. Common Stock 0.1% 890K $2M — $1.45 $1.21 (−17%) 2026-03-31
HYPR Hyperfine, Inc. Class A Common Stock 0.0% 899K $971K — $1.44 $0.80 (−44%) 2026-03-31
AUTL Autolus Therapeutics Plc 0.0% 698K $964K — $1.84 $1.90 (+3%) 2026-03-31
TNYA Tenaya Therapeutics, Inc. Common Stock 0.0% 916K $632K — $2.85 $0.60 (−79%) 2026-03-31
Related ▾
CME stockPL stockASTS stockRVMD stockAll hedge funds
FAQ ▾

What are Alphabet Inc's largest holdings?

As of the latest 13F: CME Group Inc. 25.6%, Planet Labs PBC 24.5%, AST SpaceMobile, Inc. Class A Common Stock 18.5%, Revolution Medicines, Inc. Common Stock 8.0%, Arm Holdings Plc 7.4%.

How big is Alphabet Inc's 13F portfolio?

$4.0B across 26 disclosed U.S.-equity positions.

What is Alphabet Inc's 3-year performance?

+155% (13F-replication, price return), +76 pts vs the S&P 500. Not an audited fund return.

Where does this data come from?

U.S. SEC Form 13F-HR institutional holdings filings.

Sourced from SEC Form 13F-HR filings · Not investment advice ▾
SEC EDGAR 13F
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.

Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.